Alba One of Two Panelists for Jacksonville Women Lawyers Association Meeting
13 November 2017
Public Affairs Director Erika Alba was a panelist at a Jacksonville Women Lawyers Association meeting this month about how women can “be heard” in City Hall and in Tallahassee, the Jacksonville Daily Record reported.
“If you really want to be in the process, become an expert in an industry,” she said. “Lobbying is a lot like litigation. You have to be precise and you have to know your issue well.”
She also stressed the importance of maintaining a high standard of ethics: “Always tell the truth. If someone asks about who is your opposition, tell them. That’s a discovery question. The first day you walk into the capital, you have your name and your integrity. Make sure you have that at the end of your career.”
“If you really want to be in the process, become an expert in an industry,” she said. “Lobbying is a lot like litigation. You have to be precise and you have to know your issue well.”
She also stressed the importance of maintaining a high standard of ethics: “Always tell the truth. If someone asks about who is your opposition, tell them. That’s a discovery question. The first day you walk into the capital, you have your name and your integrity. Make sure you have that at the end of your career.”
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”